A Phase 1 Study of TSR-022 an Anti-TIM-3 Monoclonal Antibody in Patients With Advanced Solid Tumors (AMBER)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Advanced or Metastatic Solid Tumors
Age: Between 18 - 80 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required